IDO and outcomes in ovarian cancer.
Nelson
Brad H
BH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology; D011379:Prognosis; D014364:Tryptophan / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology
D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D014364:Tryptophan; D017239:Paclitaxel; C525396:1-methyltryptophan